Kirsten rat sarcoma viral oncogene (KRAS) is a common driver oncogene mutation in NSCLC that plays a crucial role in cancer development and evolution.4,5 As a member of the GTPase family, it functions to catalyze GTP hydrolysis.6KRAS mutations are common in NSCLC; the mutation sites include amino acids 12, 13, and 61, with the G12C mutation being the most common, followed by G12V, G12D, and G12A mutations.7,8KRAS mutations reduce GTPase activity, leading to sustained KRAS activation and increased signaling in the downstream pathways. This evidence concerns the gene KRAS and non-small cell lung carcinoma.